Related references
Note: Only part of the references are listed.Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab
Ruby F. Meredith et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Mike Sathekge et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models
Benjamin B. Kasten et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
S. Nilsson et al.
ANNALS OF ONCOLOGY (2016)
Large scale accelerator production of 225AC: Effective cross sections for 78-192 MeV protons incident on 232Th targets
J. R. Griswold et al.
APPLIED RADIATION AND ISOTOPES (2016)
Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles
Katja Behling et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy
Ana P. Kiess et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic
Mehran Makvandi et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223
Robert Coleman
SEMINARS IN NUCLEAR MEDICINE (2016)
Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
Takahiro Yoshida et al.
ONCOTARGET (2016)
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine
Ho Sze Chan et al.
EJNMMI RESEARCH (2016)
Long-Term Toxicity of 213Bi-Labelled BSA in Mice
Laetitia Dorso et al.
PLOS ONE (2016)
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
Damian J. Green et al.
BLOOD (2015)
Absorbed Doses and Risk Estimates of 211At-MX35 F(ab′)2 in Intraperitoneal Therapy of Ovarian Cancer Patients
Elin Cederkrantz et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy
Kazuma Ogawa et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
Bystander effects and radiotherapy
Alicia Marin et al.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2015)
Production of 211At by a vertical beam irradiation method
Kotaro Nagatsu et al.
APPLIED RADIATION AND ISOTOPES (2014)
Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
Ruby F. Meredith et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Radium Ra 223 Dichloride Injection: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2014)
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C. Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
PRELIMINARY PRODUCTION OF 211At AT THE TEXAS A&M UNIVERSITY CYCLOTRON INSTITUTE
Thomas Michael Martin et al.
HEALTH PHYSICS (2014)
Production of α-particle emitting 211At using 45 MeV α-beam
Gyehong Kim et al.
PHYSICS IN MEDICINE AND BIOLOGY (2014)
Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy
Mark F. McLaughlin et al.
PLOS ONE (2013)
What is the role of the Bystander response in radionuclide therapies?
Darren Brady et al.
FRONTIERS IN ONCOLOGY (2013)
Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200 MeV
J. W. Weidner et al.
APPLIED RADIATION AND ISOTOPES (2012)
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
S. Nilsson et al.
EUROPEAN JOURNAL OF CANCER (2012)
Significant systemic therapeutic effects of high-LET immunoradiation by 212pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice
Zongqing Tan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Design and evaluation of an external high-current target for production of 211At
K. Gagnon et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2012)
LaPO4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides
Jonathan Woodward et al.
BIOCONJUGATE CHEMISTRY (2011)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
Astatine-211: Production and Availability
Michael R. Zalutsky et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Targeted Alpha Therapy with Bi-213
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors
Freddy E. Escorcia et al.
CANCER RESEARCH (2010)
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
Todd L. Rosenblat et al.
CLINICAL CANCER RESEARCH (2010)
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
D. Cordier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
Hong Song et al.
CANCER RESEARCH (2009)
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors
Jean-Francois Chatal et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2009)
Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2-A Phase I Study
Hakan Andersson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor Cells
Enken Drecoll et al.
PLOS ONE (2009)
Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases
Min-Yuan Chang et al.
BIOCONJUGATE CHEMISTRY (2008)
Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors
Matthias Miederer et al.
CLINICAL CANCER RESEARCH (2008)
Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6
Michael R. Zalutsky et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers
Stavroula Sofou et al.
BIOCONJUGATE CHEMISTRY (2007)
Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies
Michael R. Zalutsky et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes
Michael R. McDevitt et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer
Emma Y. Song et al.
CANCER BIOLOGY & THERAPY (2007)
Interim analysis of oxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
Chand Raja et al.
CANCER BIOLOGY & THERAPY (2007)
A kit method for the high level synthesis of [211At]MABG
Ganesan Vaidyanathan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization
Jaspreet Singh Jaggi et al.
PLOS ONE (2007)
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells
Claudia Friesen et al.
CANCER RESEARCH (2007)
Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
JS Jaggi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model
JP Norenberg et al.
CLINICAL CANCER RESEARCH (2006)
Intralesional targeted alpha therapy for metastatic melanoma
BJ Allen et al.
CANCER BIOLOGY & THERAPY (2005)
α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2
DE Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Renal tubulointerstitial changes after internal irradiation with α-particle-emitting actinium daughters
JS Jaggi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Melanoma therapy via peptide-targeted α-radiation
YB Miao et al.
CLINICAL CANCER RESEARCH (2005)
New insights on cell death from radiation exposure
KM Prise et al.
LANCET ONCOLOGY (2005)
A new internal target system for production of 211At on the cyclotron U-120M
O Lebeda et al.
APPLIED RADIATION AND ISOTOPES (2005)
First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases
S Nilsson et al.
CLINICAL CANCER RESEARCH (2005)
Targeting of radio-isotopes for cancer therapy
DE Milenic et al.
CANCER BIOLOGY & THERAPY (2004)
Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: A dose deescalation study
WA Bethge et al.
TRANSPLANTATION (2004)
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers
RR Yuan et al.
BLOOD (2004)
Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters
KA Hamacher et al.
MEDICAL PHYSICS (2001)
Dry-distillation of astatine-211 from irradiated bismuth targets:: a time-saving procedure with high recovery yields
S Lindegren et al.
APPLIED RADIATION AND ISOTOPES (2001)
Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors
SJ Kennel et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Share Paper
